News & Updates
Filter by Specialty:

OGSM 2024 examines how AI can improve women’s health
The 31st Congress of the Obstetrical and Gynaecological Society of Malaysia (OGSM) took place at Sabah International Convention Centre in Kota Kinabalu on 4–7 July 2024. The congress with the theme of “Intelligence in O&G: Real or Artificial?” explored the role of artificial intelligence (AI) in women’s health from adolescent onwards and included both obstetrics and gynecology.
OGSM 2024 examines how AI can improve women’s health
10 Sep 2024
High leptin levels linked to lower risk of Alzheimer’s disease
A study has recently observed the possible protective effect of leptin against the development of Alzheimer’s disease (AD) by improving insulin sensitivity.
High leptin levels linked to lower risk of Alzheimer’s disease
09 Sep 2024
Vitamin D deficiency tied to higher T2D risk
Increased serum concentration of 25(OH)D appears to contribute to a reduced risk of type 2 diabetes (T2D) across the glycaemic spectrum below the threshold for diabetes, reports a study. Improving the lipid profile may be partly responsible for the favourable association.
Vitamin D deficiency tied to higher T2D risk
09 Sep 2024
Conservative excisional margin for small MIS tied to low recurrence
For small-sized melanoma in situ (MIS; <10 mm) on low-risk body sites, wide local excision (WLE) using a 5-mm margin was associated with a low rate of recurrence, a retrospective case series study has shown.
Conservative excisional margin for small MIS tied to low recurrence
09 Sep 2024
Four-drug pill beats three separate meds in difficult-to-treat hypertension
For individuals with difficult-to-treat hypertension who are struggling with three separate medications, a single pill that combines four blood pressure (BP)-lowering drugs may help with BP control, as shown in the phase III QUADRO trial.
Four-drug pill beats three separate meds in difficult-to-treat hypertension
07 Sep 2024
SGLT-2 inhibitors may prevent dementia in adults with T2D
Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.